Treatment
-
Missing the MarkOnly one-third of new cancer therapies or drug combinations tested in phase III clinical trials prove to be better than the standard of care. Researchers explain why and how they are aiming to improve the odds.
by Sue Rochman
-
Q&A
Age Is More Than a NumberGeriatric oncologist Harvey Jay Cohen shines a spotlight on older people with cancer.
by Jocelyn Selim
-
Forward Look
Bridging the DistanceQ&A with medical oncologist Ana María López, medical director of the telemedicine program at the University of Arizona Cancer Center in Tucson.
by Sue Rochman
-
Forward Look
Treading Carefully With Medical ScansTo reduce your long-term cancer risk, make sure the tests are justified.
by Ingfei Chen
-
Forward Look
A Trojan Horse to Fight CancerAn experimental treatment shows the potential of a new family of targeted drugs.
by Stephen Ornes
-
Forward Look
A Diabetes Drug for Cancer?Lab results spur researchers to test low-cost medication on humans.
by Stephen Ornes
-
The Survival GapIn the Nowhere Land between adult and pediatric cancer treatment, young adults face survival rates that have missed out on the gains seen by other age groups. Can new efforts help them improve their outcomes?
by Charlotte Huff
-
Forward Look
When Is “Cancer” Not Cancer?Does the word “cancer” discourage patients with very early disease from fully considering all their options?
by Stephen Ornes
-
Forward Look
The Avastin Roller CoasterUps and downs keep coming for Avastin as studies report on its effects for different cancers.
by Sue Rochman
-
Clinical Trials Game-Changer?A new type of clinical trial aims to identify which drug is the best fit for each patient's tumor. Can this innovative model expedite new drug approvals?
by Sue Rochman
